{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-046459","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.730500+00:00","generated_at":"2026-06-03T14:11:39.935650+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet reports preclinical data for ADI-270, on track for IND filing in Q2 2024","bullets":["ADI-270 demonstrated robust anti-tumor activity in multiple CD70+ solid and hematological cancer models.","Preclinical data selected for oral presentation at ASGCT on May 10, 2024 in Baltimore.","ADI-270 uses CD27-based targeting and armored design to counteract tumor microenvironment and host T-cell clearance.","Company confirms IND submission for renal cell carcinoma remains on track for Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-046459","json":"https://secwatch.observer/filing/0000950170-24-046459.json","markdown":"https://secwatch.observer/filing/0000950170-24-046459.md","text":"https://secwatch.observer/filing/0000950170-24-046459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024046459/0000950170-24-046459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024046459/acet-20240422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T14:11:39.935650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}